Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
- Conditions
- Breast Cancer
- Interventions
- Registration Number
- NCT03326674
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Brief Summary
CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with HER2 negative, HR positive LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting. The primary objective of the study is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone based on progression-free survival (PFS) as assessed by the Independent Radiologic Review Committee (IRC). 685 patients were enrolled.
- Detailed Description
CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone in patients with HER2 negative, HR positive locally advanced or metastatic breast cancer (LA/MBC) previously treated with a taxane in the neoadjuvant or adjuvant setting. 685 patients were enrolled, including 674 who received treatment.
Patients randomly assigned to Arm A (tesetaxel plus a reduced dose of capecitabine) are administered:
* Tesetaxel (27 mg/m2) orally once every 21 days on Day 1 of each 21-day cycle; and
* Capecitabine (825 mg/m2) orally twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle.
Patients randomly assigned to Arm B (approved dose of capecitabine alone) are administered:
* Capecitabine (1,250 mg/m2) orally twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
Dose modifications for tesetaxel and/or capecitabine are described in the study protocol.
Patients are treated until documentation of progressive disease (PD), evidence of unacceptable toxicity or other decision to discontinue treatment. Capecitabine is an oral chemotherapy agent that is considered a standard-of-care treatment in LA/MBC. The primary efficacy endpoint is PFS as assessed by the IRC. The secondary efficacy endpoints are overall survival (OS), objective response rate (ORR) as assessed by the IRC and disease control rate (DCR) as assessed by the IRC.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 685
-
Female or male patients at least 18 years of age
-
Histologically or cytologically confirmed breast cancer
-
HER2 negative disease based on local testing: American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines should be utilized for assessing HER2 status
-
HR (estrogen receptor [ER] and/or progesterone receptor [PgR]) positive disease based on local testing: ASCO/CAP guidelines should be utilized for assessing HR status
-
Measurable disease per RECIST 1.1 or bone-only disease with lytic component
-
Patients with bone-only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by computerized tomography (CT) or magnetic resonance imaging (MRI). Patients with bone-only disease without a lytic component (ie, blastic-only metastasis) are not eligible.
-
Known metastases to the CNS are permitted but not required. The following criteria apply:
- Patients must be neurologically stable and either off corticosteroids or currently treated with a maximum daily dose of 4 mg of dexamethasone (or equivalent), with no increase in corticosteroid dose within 7 days prior to randomization
- Patients with a history of CNS metastases but with no current evidence of CNS lesions following local therapy are eligible
- Patients may have CNS metastases that are stable or progressing radiologically
- Patients with current evidence of leptomeningeal disease are not eligible
- Patients may have untreated brain metastases or previously treated brain metastases, as long as no immediate local CNS-directed therapy is indicated
- Any prior whole brain radiation therapy must have been completed > 14 days prior to the date of randomization
- Prior stereotactic brain radiosurgery is permitted
- CNS surgical resection must have been completed > 28 days prior to the date of randomization; patient must have complete recovery from surgery
-
-
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
-
Prior therapy (at least one completed dose) with a taxane-containing regimen in the neoadjuvant or adjuvant setting
-
Prior therapy with an anthracycline-containing regimen in the neoadjuvant, adjuvant, or metastatic setting, where indicated by local regulation or Investigator judgment.
-
Prior endocrine therapy with or without a CDK 4/6 inhibitor unless endocrine therapy is not indicated (ie, short relapse-free interval while on adjuvant endocrine therapy [endocrine resistance]; rapidly progressing disease/visceral crisis; or endocrine intolerance). Any targeted therapies approved for HER2 negative, HR positive LA/MBC, including everolimus, are permitted as prior therapy. There is no limit to the number of prior endocrine therapies.
-
Documented disease recurrence or disease progression of: (a) locally advanced disease that is not considered curable by surgery and/or radiation; or (b) metastatic disease.
-
Adequate hematologic, hepatic and renal function, as evidenced by:
- Absolute neutrophil count (ANC) ≥ 1,500/μL without colony-stimulating factor support
- Platelet count ≥ 100,000/μL
- Hemoglobin ≥ 10 g/dL without need for hematopoietic growth factor or transfusion support
- Total bilirubin < 1.5 × upper limit of normal (ULN); does not apply to patients with Gilbert's syndrome
- Alanine aminotransferase (ALT) < 3 × ULN unless hepatic metastases are present, then < 5 × ULN
- Aspartate aminotransferase (AST) < 3 × ULN unless hepatic metastases are present, then < 5 × ULN
- Alkaline phosphatase < 2.5 × ULN unless hepatic metastases are present, then < 5 × ULN
- Calculated creatinine clearance ≥ 50 mL/min (by Cockcroft-Gault formula or local standard)
- Serum albumin ≥ 3.0 g/dL
- Prothrombin time (PT) < 1.5 × ULN or international normalized ratio (INR) < 1.3, and partial thromboplastin time (PTT) < 1.5 × ULN, unless the patient is on a therapeutic anticoagulant
-
Complete recovery to baseline or Grade 1 per National Cancer Institute (NCI) CTCAE version 5.0 from adverse effects of prior surgery, radiotherapy, endocrine therapy and other therapy, as applicable, with the exception of Grade 2 alopecia from prior chemotherapy
-
Ability to swallow an oral solid-dosage form of medication
-
A negative serum pregnancy test within 7 days prior to the first dose of Study treatment in women of childbearing potential (ie, all women except those who are post menopause for ≥ 1 year or who have a history of hysterectomy or surgical sterilization)
-
Women of childbearing potential must use an effective, non-hormonal form of contraception from Screening throughout the Treatment Phase and until 70 days after the last dose of study treatment
• Acceptable methods include: copper intrauterine devices or double barrier methods, including male/female condoms with spermicide and use of contraceptive sponge, cervical cap, or diaphragm
-
Male patients must use an effective, non-hormonal form of contraception from screening throughout the treatment phase and until 130 days after last dose of study treatment
• Acceptable methods include male/female condoms with spermicide, or vasectomy with medical confirmation of surgical success
-
Written informed consent and authorization to use and disclose health information
-
Ability to comprehend and comply with the requirements of the study
- Two or more prior chemotherapy regimens for advanced disease
- Prior treatment with a taxane in the metastatic setting
- Prior treatment with capecitabine at any dose
- Current evidence of leptomeningeal disease
- Other cancer that required therapy within the preceding 5 years other than adequately treated: (a) non-melanoma skin cancer or in situ cancer; or (b) following approval by the Medical Monitor, other cancer that has a very low risk of interfering with the safety or efficacy endpoints of the study
- Known human immunodeficiency virus infection, unless well controlled. Patients who are on an adequate antiviral regimen with no evidence of active infection are considered well controlled.
- Active hepatitis B or active hepatitis C infection
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study
- Presence of neuropathy > Grade 1 per NCI CTCAE version 5.0
- History of hypersensitivity to taxanes; hypersensitivity to the solvent does not preclude patient participation in this study
- Anticancer treatment, including endocrine therapy, radiotherapy (except stereotactic brain radiosurgery), chemotherapy, biologic therapy, or therapy in an investigational clinical study, ≤ 14 days prior to the date of randomization
- Major surgery ≤ 28 days prior to the date of randomization; patient must have complete recovery from surgery
- Less than 2 weeks or 5 plasma half-lives (whichever is greater) since last use of a medication or ingestion of an agent, beverage or food that is a known clinically relevant strong inhibitor or known clinically relevant inducer of the cytochrome P450 (CYP) 3A pathway (patients should discontinue taking any regularly taken medication that is a strong inhibitor or inducer of the CYP3A pathway)
- History of hypersensitivity or unexpected reactions to capecitabine, other fluoropyrimidine agents or any of their ingredients
- Known dihydropyrimidine dehydrogenase (DPD) deficiency. Testing for DPD deficiency must be performed where required by local regulations, using a validated method that is approved by local health authorities.
- Pregnant or breastfeeding
- If, in the opinion of the Investigator, the patient is deemed unwilling or unable to comply with the requirements of the study
- Treatment with brivudine, sorivudine or its chemically-related analogs ≤ 28 days prior to the date of randomization
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A: Tesetaxel (oral) and capecitabine (oral) Tesetaxel and Capecitabine Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle Arm B: Capecitabine (oral) Capecitabine Capecitabine (1,250 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
- Primary Outcome Measures
Name Time Method PFS as assessed by the IRC Approximately 2.5-3.0 years
- Secondary Outcome Measures
Name Time Method ORR as assessed by the IRC Approximately 2.5-3.0 years OS Approximately 5.0-5.5 years DCR as assessed by the IRC Approximately 2.5-3.0 years Central nervous system (CNS) ORR as assessed by the CNS IRC in patients with CNS metastases at baseline Approximately 2.5-3.0 years CNS PFS as assessed by the CNS IRC in patients with CNS metastases at baseline or a history of CNS metastases and in the intent-to-treat (ITT) population Approximately 2.5-3.0 years CNS OS in patients with CNS metastases at baseline or a history of CNS metastases Approximately 2.5-3.0 years
Trial Locations
- Locations (205)
Cancer Treatment Centers of America - Western Regional Medical Center
🇺🇸Goodyear, Arizona, United States
Arizona Oncology Associates, P.C. - HOPE
🇺🇸Tucson, Arizona, United States
Ironwood Cancer and Research Centers
🇺🇸Chandler, Arizona, United States
Hartford Healthcare
🇺🇸Hartford, Connecticut, United States
SMHC Cancer Care and Blood Disorders
🇺🇸Biddeford, Maine, United States
Regional Cancer Care Associates
🇺🇸East Brunswick, New Jersey, United States
Jackson Oncology Associates
🇺🇸Jackson, Mississippi, United States
New Jersey Hematology Oncology Associates
🇺🇸Brick, New Jersey, United States
Oncology Hematology West, P.C. dba Nebraska Cancer Specialists
🇺🇸Papillion, Nebraska, United States
Ludwig Boltzmann Institut fur Klinische Onkologie und Photodynamische Therapie
🇦🇹Wien, Austria
Peninsula and South Eastern Haematology and Oncology Group
🇦🇺Frankston, Victoria, Australia
Centre Hospitalier Universitaire de Sherbrooke CIUSSS de lEstrie CHUS patyre
🇨🇦Sherbrooke, Quebec, Canada
St. Elisabethgruppe GmbH Marien Hospital Witten Brustzentrum
🇩🇪Witten, Rhineland-Palatinate, Germany
University of Pécs Department of Oncotherapy
🇭🇺Pécs, Hungary
Semmelweis University
🇭🇺Budapest, Hungary
Szpitale Pomorskie Oddział Onkologii i Radioterapii Powstania
🇵🇱Gdynia, Poland
Onko-Dent G.L.Slomian
🇵🇱Żory, Poland
Onkologikoa
🇪🇸San Sebastián, Gipuzkoa, Spain
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei City, Taiwan
Chulabhorn Hospital
🇹🇭Bangkok, Thailand
Kryviy Rih Onkology Dispensary
🇺🇦Kryvyi Rih, Ukraine
Royal Cornwall Hospital Oncology Trials, Sunrise Centre
🇬🇧Truro, Cornwall, United Kingdom
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Central City Clinical Hospital, City Oncology Center
🇺🇦Úzhgorod, Ukraine
James M. Stockman Cancer Institute
🇺🇸Frederick, Maryland, United States
GBMC Cancer Center
🇺🇸Baltimore, Maryland, United States
Forrest General Cancer Center/Hattiesburg Clinic
🇺🇸Hattiesburg, Mississippi, United States
UCLA Medical Center
🇺🇸Los Angeles, California, United States
University of Chicago Medical Center - Duchossois Center for Advanced Medicine (DCAM)
🇺🇸Chicago, Illinois, United States
St. Michael's Hospital
🇨🇦Toronto, Ontario, Canada
Texas Oncology - Memorial City
🇺🇸Houston, Texas, United States
Westside Surgical Hospital and Breast Center
🇺🇸Houston, Texas, United States
Oncology Consultants
🇺🇸Houston, Texas, United States
California Cancer Associates for Research and Excellence
🇺🇸San Marcos, California, United States
Carti Cancer Center
🇺🇸Little Rock, Arkansas, United States
Pacific Cancer Medical Center
🇺🇸Anaheim, California, United States
Genesis Cancer Center
🇺🇸Hot Springs, Arkansas, United States
Cancer Specialists of North Florida
🇺🇸Jacksonville, Florida, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Broome Oncology, LLC
🇺🇸Johnson City, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Cancer Treatment Centers of America - Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
Hope Cancer Center of East Texas
🇺🇸Tyler, Texas, United States
Bon Secours St. Francis
🇺🇸Midlothian, Virginia, United States
Virginia Cancer Institute
🇺🇸Richmond, Virginia, United States
Overlake Medical Center
🇺🇸Bellevue, Washington, United States
Kadlec Regional Medical Center
🇺🇸Kennewick, Washington, United States
Swedish Cancer Center
🇺🇸Seattle, Washington, United States
Northwest Medical Specialties
🇺🇸Tacoma, Washington, United States
Sydney Adventist Hospital
🇦🇺Wahroonga, New South Wales, Australia
Border Medical Oncology
🇦🇺Albury, New South Wales, Australia
Mater Cancer Care Centre
🇦🇺South Brisbane, Queensland, Australia
Flinders Medical Centre
🇦🇺Bedford Park, Australia
Universitätsklinik Onkologie Landeskkrankenhaus
🇦🇹Salzburg, Austria
Facharzt für Frauenheilkunde und Geburtshilfe Spezialist für Brustchirurgie und Brustkrebs
🇦🇹Schwaz, Austria
AKH-Frauenheilkunde
🇦🇹Vienna, Austria
AZ Klina AUGUSTIJNSLEI
🇧🇪Antwerp, Belgium
UZA
🇧🇪Edegem, Belgium
Institut Jules Bordet
🇧🇪Brussels, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
CHC-Sant Joseph Oncology-Hematology
🇧🇪Liège, Belgium
The Moncton Hospital
🇨🇦Moncton, New Brunswick, Canada
Hopital Maisonneuve-Rosemont
🇨🇦Montréal, Quebec, Canada
Center Hospitalier de Montreal CHUM McPeak Sirois
🇨🇦Montréal, Quebec, Canada
CIUSSS de Centre-Ouest-de-l'Île-de-Montréal Jewish General Hospital
🇨🇦Montréal, Quebec, Canada
CHU de Quebec-University Laval
🇨🇦Québec, Canada
NH Hospital a.s. Nemocnice Hořovice Onkologie
🇨🇿Hořovice, Czechia
Onkologicka Klinika (Fakultni Nemocnice v Motole)
🇨🇿Praha, Czechia
CHRU J. Minjoz Service Oncologie
🇫🇷Besançon, France
Centre François Baclesse Service the Recherche Clinique
🇫🇷Caen, France
Hospices Civils de Lyon Sud Oncologie Medicale
🇫🇷Pierre-Benite, France
Institut Curie - Hopital Rene Huguenin
🇫🇷Saint-Cloud, France
Centre Hospitalier Regional et Universitaire de Tours CHRU
🇫🇷Tours, France
St. Elisabeth-Krankenhaus GmbH
🇩🇪Köln, NRW, Germany
Arzt der Studienzentrale Universitätsklinikum Erlangen
🇩🇪Erlangen, Berlin, Germany
UKSH, Campus Kiel Klinik für Gynäkologie und Geburtshilfe
🇩🇪Kiel, Germany
Mammazentrum HH am Krankenhaus Jerusalem
🇩🇪Hamburg, Germany
Staedtisches Klinikum Lueneburg gGmbH Brustzentrum und gynaekologisches Krebszentrum der Frauenklinik
🇩🇪Lueneburg, Germany
Helios Klinikum Berlin-Buch
🇩🇪Berlin, Germany
Uzsoki utcai kórház
🇭🇺Budapest, Hungary
Military Hospital State Health Center
🇭🇺Budapest, Hungary
LMU Klinikum der Universität München Breast Cancer
🇩🇪München, Germany
Technische Universität München Klinikum rechts der Isar Klinik und Poliklinik für Frauenheilkunde
🇩🇪München, Germany
Országos Onkológiai Intézet
🇭🇺Budapest, Hungary
Szabolcs Szatmar Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz
🇭🇺Nyíregyháza, Hungary
Istituto Europeo di Oncologia (IEO)
🇮🇹Milano, Italy
Ospedale San Raffaele - Medical Oncology Dept.
🇮🇹Milano, Italy
Centro Oncologico Modenese
🇮🇹Modena, Italy
S.C. Oncologia/Az. Osp.Ra. S Maria Terni
🇮🇹Terni, Italy
Dong-A University Hospital
🇰🇷Busan, Korea, Republic of
Kyungpook National University Hospital
🇰🇷Daegu, Korea, Republic of
National Cancer Center
🇰🇷Goyang, Korea, Republic of
Gangnam Severance Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Ajou University Hospital
🇰🇷Suwon, Korea, Republic of
Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Oddzial Onkologii z Pododdzialem Chemoioterapii
🇵🇱Olsztyn, Poland
St. Vincents Hospital
🇰🇷Suwon, Korea, Republic of
Wilmed
🇵🇱Warsaw, Poland
Mrukmed
🇵🇱Rzeszów, Poland
Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej Centrum Onkologii-Instytut
🇵🇱Warszawa, Poland
John Hopkins Singapore International Medical Centre
🇸🇬Singapore, Singapore
State Oncology Clinical Dispansery
🇷🇺Saint Petersburg, Russian Federation
National Cancer Centre Singapore
🇸🇬Singapore, Singapore
National University Hospital
🇸🇬Singapore, Singapore
Hospital Quironsalud Barcelona
🇪🇸Barcelona, Spain
Institut Catala d'Oncologia
🇪🇸Barcelona, Spain
Hospital Teresa Herrera Materno-Infantil (CHUAC)
🇪🇸A Coruña, Spain
HU San Pedro de Alcantara
🇪🇸Cáceres, Spain
Hospital Universitario Ramon y Cajal Servicio de Oncologia
🇪🇸Madrid, Spain
Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Hospital Universitario Virgen de la Victoria
🇪🇸Málaga, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Changhua Christian Hospital
🇨🇳Taichung, Taiwan
Hospital Universitario Miguel Servet Paseo Isabel la Catolica 1-3 Edificio de Maternidad
🇪🇸Zaragoza, Spain
Chi Mei Medical Center
🇨🇳Tainan City, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital Linkou Branch
🇨🇳Taoyuan, Taiwan
Buddhachinaraj Hospital
🇹🇭Phitsanulok, Thailand
Dnipropetrovsk City Multifield Clinical Hospital #4
🇺🇦Dnipro, Ukraine
Communal Non-Profit Enterprise "Regional Center of Oncology"
🇺🇦Kharkiv, Ukraine
Municipal Institution of Lviv Regional Council - Lviv Oncology Regional Treatment Diagnostic Center
🇺🇦Lviv, Ukraine
Podilskiy Regional Center of Oncology
🇺🇦Vinnytsia, Ukraine
Communal Institution "Zaporizhzhia Regional Clinical Oncological Dispensary"
🇺🇦Zaporizhzhia, Ukraine
Cancer Centre, Guy's Hospital
🇬🇧London, United Kingdom
Nottingham University Hospitals NHS Trust
🇬🇧Nottingham, United Kingdom
Sharp Memorial Hospital
🇺🇸San Diego, California, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Virginia Piper Cancer Institute, Allina Health
🇺🇸Minneapolis, Minnesota, United States
Mercy Clinic Oncology and Hematology
🇺🇸Oklahoma City, Oklahoma, United States
Sarah Cannon Research Institute at Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
San Luis Obispo Oncology & Hematology Health Center
🇺🇸San Luis Obispo, California, United States
Innovative Clinical Research Institute
🇺🇸Whittier, California, United States
University of California San Francisco - Helen Diller Family Comprehensive Cancer Center
🇺🇸San Francisco, California, United States
Rocky Mountain Cancer Center
🇺🇸Lakewood, Colorado, United States
Compassionate Care Research Group
🇺🇸Fountain Valley, California, United States
CBCC Global Research, Inc.
🇺🇸Bakersfield, California, United States
Cancer Care - Torrance Memorial Physician Network
🇺🇸Redondo Beach, California, United States
Sarah Cannon Research Institute - Florida Cancer Specialists
🇺🇸Fort Myers, Florida, United States
Western Connecticut Health Network
🇺🇸Danbury, Connecticut, United States
Stanford Cancer Center / Cancer Clinical Trials
🇺🇸Stanford, California, United States
Memorial Healthcare System
🇺🇸Hollywood, Florida, United States
Cancer and Hematology Centers of Western Michigan
🇺🇸Grand Rapids, Michigan, United States
University of Maryland - Greenebaum Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Cancer Treatment Centers of America
🇺🇸Newnan, Georgia, United States
Miami Cancer Institute
🇺🇸Miami, Florida, United States
Mercy Cancer Center
🇺🇸Joplin, Missouri, United States
Baptist Health Lexington
🇺🇸Lexington, Kentucky, United States
University Cancer and Blood Center
🇺🇸Athens, Georgia, United States
Maryland Oncology Hematology, P.A.
🇺🇸Rockville, Maryland, United States
Florida Cancer Specialists and Research Institute - Panhandle Region
🇺🇸Tallahassee, Florida, United States
American Health Network
🇺🇸Indianapolis, Indiana, United States
Orchard Healthcare Research
🇺🇸Skokie, Illinois, United States
Chevy Chase Health Care Center/ RCCA
🇺🇸Chevy Chase, Maryland, United States
Texas Oncology - Bedford
🇺🇸Bedford, Texas, United States
Magee-Women's Hospital of UPMC
🇺🇸Pittsburgh, Pennsylvania, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
West Cancer Center
🇺🇸Germantown, Tennessee, United States
Mercy Hospital St. Louis, David C. Pratt Cancer Center
🇺🇸Saint Louis, Missouri, United States
St. Vincent Frontier Cancer Center
🇺🇸Billings, Montana, United States
The Valley Hospital
🇺🇸Ridgewood, New Jersey, United States
New York Oncology Hematology, P.C.
🇺🇸Albany, New York, United States
Hematology Oncology Associates of Central New York, P.C.
🇺🇸East Syracuse, New York, United States
Ohio State University Comprehensive Cancer Center, Stephanie Spielman Comprehensive Breast Center
🇺🇸Columbus, Ohio, United States
New Mexico Cancer Care Alliance - Southwest Gynecology Oncology
🇺🇸Albuquerque, New Mexico, United States
Regional Cancer Care Associates, LLC-Sparta
🇺🇸Sparta, New Jersey, United States
New York Cancer and Blood Specialists
🇺🇸East Setauket, New York, United States
Lehigh Valley Health Network
🇺🇸Allentown, Pennsylvania, United States
Virginia Oncology Associates
🇺🇸Norfolk, Virginia, United States
Texas Oncology - Medical City Dallas
🇺🇸Dallas, Texas, United States
Texas Oncology - Dallas Presbyterian Hospital
🇺🇸Dallas, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
🇺🇸Dallas, Texas, United States
St. John of God Subiaco Hospital
🇦🇺Perth, Western Australia, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Monash Medical Centre
🇦🇺Clayton, Victoria, Australia
Breast Cancer Research Centre
🇦🇺Nedlands, Western Australia, Australia
Clinique Sainte Anne - Strasbourg Oncologie Liberale
🇫🇷Strasbourg, France
QEII Health Sciences Centre - Nova Scotia Cancer Centre
🇨🇦Halifax, Nova Scotia, Canada
McGill University Health Center
🇨🇦Montréal, Quebec, Canada
Onkologicka Klinika FN Olomouc
🇨🇿Olomouc, Czechia
Centre Eugène Marquis
🇫🇷Rennes, France
Onkologicka Klinika (Vseobecna Fakultni Nemocnici v Praze )
🇨🇿Praha, Czechia
InVO - Institut für Versorgungsforschung
🇩🇪Koblenz, Rhineland-Palatinate, Germany
Charité Universitätsmedizin Berlin-Campus Benjamin Franklin Klinik für Hämatologie, Onkologie und Tumorimmunologie
🇩🇪Berlin, Germany
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Federal State Budgetary Institution Research Institute of Oncology named after N.N. Petrov of the Ministry of Health of the Russian Federation
🇷🇺Saint Petersburg, Russian Federation
Althaia Hospital Sant Joan de Deu
🇪🇸Barcelona, Manresa, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
IOB_Hospital Ruber Internacional
🇪🇸Madrid, Spain
Centro Oncológico de Galicia
🇪🇸La Coruña, Spain
King Chulalongkorn Memorial Hospital
🇹🇭Bangkok, Thailand
National Cancer Institute
🇺🇦Kyiv, Ukraine
Hertford County Hospital
🇬🇧Hertford, United Kingdom
Oklahoma Cancer Specialists and Research Institute, LLC
🇺🇸Tulsa, Oklahoma, United States
Cancer Research Collaboration and Breast Link
🇺🇸Santa Ana, California, United States
University of Miami Sylvester Comprehensive Cancer Center / Sylvester at Plantation
🇺🇸Plantation, Florida, United States
Florida Cancer Specialists and Research Institute
🇺🇸West Palm Beach, Florida, United States
Florida Cancer Affiliates - Ocala
🇺🇸Ocala, Florida, United States
St. Joseph Heritage Healthcare
🇺🇸Fullerton, California, United States
HCA Midwest Health
🇺🇸Kansas City, Missouri, United States
Orlando Health
🇺🇸Orlando, Florida, United States
University of North Carolina Lineberger Cancer Center
🇺🇸Chapel Hill, North Carolina, United States